View in EDS PDF Full Text

Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients.

Saved in:
Bibliographic Details
Title: Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients.
Authors: Herbst, Roy S., Gettinger, Scott N., Horn, Leora, Lawrence, Donald P., Hodi, F. Stephen, Soria, Jean-Charles, Kowanetz, Marcin, Fine, Gregg D., Rost, Sandra, Leabman, Maya, Xiao, Yuanyuan, Mokatrin, Ahmad, Koeppen, Hartmut, Hegde, Priti S., Mellman, Ira, Chen, Daniel S., Hamid, Omid, Gordon, Michael S., Sosman, Jeffery A., McDermott, David F.
Source: Nature. 11/27/2014, Vol. 515 Issue 7528, p563-567. 5p.
Subjects: Cancer cells, Tumors, T cells, Cytotoxins, Fractalkine
Abstract: The development of human cancer is a multistep process characterized by the accumulation of genetic and epigenetic alterations that drive or reflect tumour progression. These changes distinguish cancer cells from their normal counterparts, allowing tumours to be recognized as foreign by the immune system. However, tumours are rarely rejected spontaneously, reflecting their ability to maintain an immunosuppressive microenvironment. Programmed death-ligand 1 (PD-L1; also called B7-H1 or CD274), which is expressed on many cancer and immune cells, plays an important part in blocking the 'cancer immunity cycle' by binding programmed death-1 (PD-1) and B7.1 (CD80), both of which are negative regulators of T-lymphocyte activation. Binding of PD-L1 to its receptors suppresses T-cell migration, proliferation and secretion of cytotoxic mediators, and restricts tumour cell killing. The PD-L1-PD-1 axis protects the host from overactive T-effector cells not only in cancer but also during microbial infections. Blocking PD-L1 should therefore enhance anticancer immunity, but little is known about predictive factors of efficacy. This study was designed to evaluate the safety, activity and biomarkers of PD-L1 inhibition using the engineered humanized antibody MPDL3280A. Here we show that across multiple cancer types, responses (as evaluated by Response Evaluation Criteria in Solid Tumours, version 1.1) were observed in patients with tumours expressing high levels of PD-L1, especially when PD-L1 was expressed by tumour-infiltrating immune cells. Furthermore, responses were associated with T-helper type 1 (TH1) gene expression, CTLA4 expression and the absence of fractalkine (CX3CL1) in baseline tumour specimens. Together, these data suggest that MPDL3280A is most effective in patients in which pre-existing immunity is suppressed by PD-L1, and is re-invigorated on antibody treatment. [ABSTRACT FROM AUTHOR]
Copyright of Nature is the property of Springer Nature and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Database: Psychology and Behavioral Sciences Collection
FullText Links:
  – Type: pdflink
Text:
  Availability: 0
Header DbId: pbh
DbLabel: Psychology and Behavioral Sciences Collection
An: 99713964
AccessLevel: 6
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AR" term="%22Herbst%2C+Roy+S%2E%22">Herbst, Roy S.</searchLink><br /><searchLink fieldCode="AR" term="%22Gettinger%2C+Scott+N%2E%22">Gettinger, Scott N.</searchLink><br /><searchLink fieldCode="AR" term="%22Horn%2C+Leora%22">Horn, Leora</searchLink><br /><searchLink fieldCode="AR" term="%22Lawrence%2C+Donald+P%2E%22">Lawrence, Donald P.</searchLink><br /><searchLink fieldCode="AR" term="%22Hodi%2C+F%2E+Stephen%22">Hodi, F. Stephen</searchLink><br /><searchLink fieldCode="AR" term="%22Soria%2C+Jean-Charles%22">Soria, Jean-Charles</searchLink><br /><searchLink fieldCode="AR" term="%22Kowanetz%2C+Marcin%22">Kowanetz, Marcin</searchLink><br /><searchLink fieldCode="AR" term="%22Fine%2C+Gregg+D%2E%22">Fine, Gregg D.</searchLink><br /><searchLink fieldCode="AR" term="%22Rost%2C+Sandra%22">Rost, Sandra</searchLink><br /><searchLink fieldCode="AR" term="%22Leabman%2C+Maya%22">Leabman, Maya</searchLink><br /><searchLink fieldCode="AR" term="%22Xiao%2C+Yuanyuan%22">Xiao, Yuanyuan</searchLink><br /><searchLink fieldCode="AR" term="%22Mokatrin%2C+Ahmad%22">Mokatrin, Ahmad</searchLink><br /><searchLink fieldCode="AR" term="%22Koeppen%2C+Hartmut%22">Koeppen, Hartmut</searchLink><br /><searchLink fieldCode="AR" term="%22Hegde%2C+Priti+S%2E%22">Hegde, Priti S.</searchLink><br /><searchLink fieldCode="AR" term="%22Mellman%2C+Ira%22">Mellman, Ira</searchLink><br /><searchLink fieldCode="AR" term="%22Chen%2C+Daniel+S%2E%22">Chen, Daniel S.</searchLink><br /><searchLink fieldCode="AR" term="%22Hamid%2C+Omid%22">Hamid, Omid</searchLink><br /><searchLink fieldCode="AR" term="%22Gordon%2C+Michael+S%2E%22">Gordon, Michael S.</searchLink><br /><searchLink fieldCode="AR" term="%22Sosman%2C+Jeffery+A%2E%22">Sosman, Jeffery A.</searchLink><br /><searchLink fieldCode="AR" term="%22McDermott%2C+David+F%2E%22">McDermott, David F.</searchLink>
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22Nature%22">Nature</searchLink>. 11/27/2014, Vol. 515 Issue 7528, p563-567. 5p.
– Name: Subject
  Label: Subjects
  Group: Su
  Data: <searchLink fieldCode="DE" term="%22Cancer+cells%22">Cancer cells</searchLink><br /><searchLink fieldCode="DE" term="%22Tumors%22">Tumors</searchLink><br /><searchLink fieldCode="DE" term="%22T+cells%22">T cells</searchLink><br /><searchLink fieldCode="DE" term="%22Cytotoxins%22">Cytotoxins</searchLink><br /><searchLink fieldCode="DE" term="%22Fractalkine%22">Fractalkine</searchLink>
– Name: Abstract
  Label: Abstract
  Group: Ab
  Data: The development of human cancer is a multistep process characterized by the accumulation of genetic and epigenetic alterations that drive or reflect tumour progression. These changes distinguish cancer cells from their normal counterparts, allowing tumours to be recognized as foreign by the immune system. However, tumours are rarely rejected spontaneously, reflecting their ability to maintain an immunosuppressive microenvironment. Programmed death-ligand 1 (PD-L1; also called B7-H1 or CD274), which is expressed on many cancer and immune cells, plays an important part in blocking the 'cancer immunity cycle' by binding programmed death-1 (PD-1) and B7.1 (CD80), both of which are negative regulators of T-lymphocyte activation. Binding of PD-L1 to its receptors suppresses T-cell migration, proliferation and secretion of cytotoxic mediators, and restricts tumour cell killing. The PD-L1-PD-1 axis protects the host from overactive T-effector cells not only in cancer but also during microbial infections. Blocking PD-L1 should therefore enhance anticancer immunity, but little is known about predictive factors of efficacy. This study was designed to evaluate the safety, activity and biomarkers of PD-L1 inhibition using the engineered humanized antibody MPDL3280A. Here we show that across multiple cancer types, responses (as evaluated by Response Evaluation Criteria in Solid Tumours, version 1.1) were observed in patients with tumours expressing high levels of PD-L1, especially when PD-L1 was expressed by tumour-infiltrating immune cells. Furthermore, responses were associated with T-helper type 1 (TH1) gene expression, CTLA4 expression and the absence of fractalkine (CX3CL1) in baseline tumour specimens. Together, these data suggest that MPDL3280A is most effective in patients in which pre-existing immunity is suppressed by PD-L1, and is re-invigorated on antibody treatment. [ABSTRACT FROM AUTHOR]
– Name: AbstractSuppliedCopyright
  Label:
  Group: Ab
  Data: <i>Copyright of Nature is the property of Springer Nature and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract.</i> (Copyright applies to all Abstracts.)
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=pbh&AN=99713964
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1038/nature14011
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        PageCount: 5
        StartPage: 563
    Subjects:
      – SubjectFull: Cancer cells
        Type: general
      – SubjectFull: Tumors
        Type: general
      – SubjectFull: T cells
        Type: general
      – SubjectFull: Cytotoxins
        Type: general
      – SubjectFull: Fractalkine
        Type: general
    Titles:
      – TitleFull: Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Herbst, Roy S.
      – PersonEntity:
          Name:
            NameFull: Gettinger, Scott N.
      – PersonEntity:
          Name:
            NameFull: Horn, Leora
      – PersonEntity:
          Name:
            NameFull: Lawrence, Donald P.
      – PersonEntity:
          Name:
            NameFull: Hodi, F. Stephen
      – PersonEntity:
          Name:
            NameFull: Soria, Jean-Charles
      – PersonEntity:
          Name:
            NameFull: Kowanetz, Marcin
      – PersonEntity:
          Name:
            NameFull: Fine, Gregg D.
      – PersonEntity:
          Name:
            NameFull: Rost, Sandra
      – PersonEntity:
          Name:
            NameFull: Leabman, Maya
      – PersonEntity:
          Name:
            NameFull: Xiao, Yuanyuan
      – PersonEntity:
          Name:
            NameFull: Mokatrin, Ahmad
      – PersonEntity:
          Name:
            NameFull: Koeppen, Hartmut
      – PersonEntity:
          Name:
            NameFull: Hegde, Priti S.
      – PersonEntity:
          Name:
            NameFull: Mellman, Ira
      – PersonEntity:
          Name:
            NameFull: Chen, Daniel S.
      – PersonEntity:
          Name:
            NameFull: Hamid, Omid
      – PersonEntity:
          Name:
            NameFull: Gordon, Michael S.
      – PersonEntity:
          Name:
            NameFull: Sosman, Jeffery A.
      – PersonEntity:
          Name:
            NameFull: McDermott, David F.
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 27
              M: 11
              Text: 11/27/2014
              Type: published
              Y: 2014
          Identifiers:
            – Type: issn-print
              Value: 00280836
          Numbering:
            – Type: volume
              Value: 515
            – Type: issue
              Value: 7528
          Titles:
            – TitleFull: Nature
              Type: main
ResultId 1